Autolus Therapeutics (NASDAQ:AUTL) Upgraded by Redburn Atlantic to Buy Rating

Redburn Atlantic upgraded shares of Autolus Therapeutics (NASDAQ:AUTL - Free Report) from a neutral rating to a buy rating in a research report report published on Friday morning, Marketbeat Ratings reports. The firm currently has $13.00 target price on the stock.

Separately, Needham & Company LLC reissued a "buy" rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Autolus Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $9.45.

Autolus Therapeutics Price Performance

Autolus Therapeutics stock traded up $0.07 during midday trading on Friday, reaching $3.08. 2,713,750 shares of the company traded hands, compared to its average volume of 1,442,194. Autolus Therapeutics has a 12 month low of $2.95 and a 12 month high of $7.45. The firm has a market capitalization of $819.56 million, a price-to-earnings ratio of -2.49 and a beta of 2.04. The business has a 50 day moving average of $3.92 and a two-hundred day moving average of $3.99.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same quarter last year, the firm earned ($0.26) EPS. As a group, equities analysts forecast that Autolus Therapeutics will post -0.84 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics during the 2nd quarter worth approximately $43,000. Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics in the third quarter valued at approximately $51,000. Bayesian Capital Management LP acquired a new stake in Autolus Therapeutics in the first quarter valued at approximately $100,000. Daiwa Securities Group Inc. grew its position in Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock valued at $55,000 after acquiring an additional 15,293 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Autolus Therapeutics during the first quarter worth approximately $108,000. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.